01110 KINGWORLD
- 0.460
- -0.005-1.08%
KINGWORLD News
Jin Huo 30th Anniversary Series Event | Longde Health Industry Park Grand Opening, Jin Huo Writes a New Chapter in the Health Industry.
On November 26, 2024, the grand opening ceremony of the Kingworld-Longde Health Industry Park was held in Shenzhen, marking the beginning of the 30th anniversary celebration of Kingworld Group. On the same day, the new product 'Foci-Kingworld Angong Niuhuang Pills' jointly launched by Foci and Kingworld was also listed and debuted, a series of milestone celebration activities indicating Kingworld Pharmaceuticals' confidence and determination to continue to write a new chapter in the medical and health industry. After four years of hard work, the Longde Park creates a new business card for Longgang Health. The Longde Health Industry Park is developed by Kingworld Pharmaceuticals (01110.HK) in accordance with the national health industry development strategy combined with the industrial development plans of Shenzhen and Longgang District.
Kingworld Medicines Launches Longde Health Industrial Park
Kingworld (01110.HK): The Longde Health Industry Park has officially been put into operation.
Grunt 26 November, kingworld (01110.HK) announced that the board of directors is pleased to announce that the Longde Health Industry Park has officially started operating since 26 November 2024. Longde Health Industry Park is located in Baolong Technology City, Longgang District, Shenzhen, China, at the heart of the East Core of Longgang District composed of the high-speed rail new town and international low-carbon city in the east of Shenzhen. Longde Health Industry Park is listed as a major project in Longgang District. The group plans to leverage the geographical advantages and policy support of the Greater Bay Area, integrate resources in the pharmaceutical industry supply chain, and further develop the Longde Health Industry Park. The board of directors believes that Longde Health Industry Park
Kingworld (01110.HK) announced that director and chairman Zhao Lisheng increased his shareholding by 1 million shares.
According to the latest equity disclosure information from the Stock Exchange on November 25, Gelonghui reported that on November 20, 2024, kingworld (01110.HK) saw its executive director and chairman Zhao Lisheng increase his shareholding by purchasing 1 million shares at an average price of HKD 0.4635 per share, involving approximately HKD 0.4635 million. After the increase, Zhao Lisheng's latest shareholding is 412,980,250 shares, with his ownership percentage rising from 66.18% to 66.34%.
Li Sheng Zhao Spends CN¥436k On Kingworld Medicines Group Stock
Ex-Kingworld Medicines Employees Face Fraud Charges
China Medical (01110.HK): Two former employees have been charged by the ICAC.
Tin Hou Pharmaceutical (01110.HK) announced that two former employees of the group have been charged by the ICAC with suspected misconduct. The defendants resigned from all positions within the group in mid-July and mid-August respectively. The group emphasized that its directors, senior management, and employees were not involved in any of the alleged misconduct by the defendants. These cases have not had any significant adverse impact on the group, as the corresponding financial impact accounts for only a very small proportion of the total assets of the group.
kingworld (01110) emphasizes that the company's directors, senior executives, and employees have not been involved in the illegal activities that the defendants are accused of.
Kingworld (01110) announced that the company noticed that the Independent Commission Against Corruption of the Hong Kong Special Administrative Region in November 2024...
KINGWORLD: Interim Report 2024
Kingworld Pharmaceutical Group (01110): Chu Xiaoping appointed as an independent non-executive director
Kingworld (01110) announced that Dr. Chu Xiaoping has been appointed as an independent non-executive director, nomination committee,...
Kingworld Appoints New Independent Director
Kingworld Medicines Unveils New Board Structure
Jinhuo Medicine (01110.HK) is innovating and creating a new engine.
With the approaching of the expectation of interest rate cuts by the Federal Reserve and the increase of policy support, the pharmaceutical sector, with its low valuation and high cost-effectiveness, has become a focus area of the market's attention. Several brokerages have predicted that after the mid-term report is released, negative factors within the pharmaceutical industry will be effectively digested, indicating that the second half of the year will be a golden opportunity to layout in this sector. Of particular interest is the recent release of the performance of Kingworld Pharmaceutical Group Co., Ltd. (referred to as 'Kingworld Pharmaceutical') for the first half of 2024, which has demonstrated strong resilience and stabilized the company's foundation in the industry's overall downturn environment. The company has long been deeply rooted in the pharmaceutical market and has a portfolio that includes domestic products.
In terms of performance, China Jinhao Pharmaceuticals (01110.HK) reported a mid-year net profit of 30.72 million RMB, a decrease of 18.6% with no dividend payment.
Kingworld (01110.HK) announced its interim performance for the six months ending in June, with a revenue of 0.526 billion RMB, a year-on-year decrease of 4.9%. Net profit was recorded at 30.72 million yuan, a decline of 18.6%, with earnings per share of 5.2 fen. No interim dividend will be distributed.
Kingworld pharmaceutical group (01110) released its interim results, with a net profit attributable to shareholders of 30.716 million yuan, a decrease of 18.58% year-on-year.
Kingworld (01110) has announced its interim performance for the six months ended June 30, 2024...
KINGWORLD: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
Kingworld Medicines Group Plans Financial Review
Kingworld (01110.HK) plans to hold a board of directors meeting on August 28 to review the mid-term performance.
Kingworld announced that the board of directors meeting will be held on Wednesday, August 28, 2024, at room 613, 6/F, Good Luck Industrial Centre, No. 808 Lai Chi Kok Road, Kowloon, Hong Kong. The purpose of the meeting is to review and approve the unaudited interim performance of the group for the six months ended June 30, 2024, and to consider the payment of interim dividends (if any), and to deal with any other matters.
KINGWORLD: NOTICE OF BOARD MEETING
Guotou Securities: The market share of listed pharmacies continues to increase, and the growth potential is expected to lead the industry.
In the context of a slowdown in the industry's growth rate, listed pharmacies are expected to achieve growth rates higher than the industry by virtue of their continuous rapid expansion of stores.
Analysis
Price Target
No Data
No Data